Tag - TLANDO

Feature

FDA advisory vote on TLANDO not a knockout for Lipocine

By Len Zehrs Although Lipocine (NASDAQ:LPCN) is disappointed by a FDA advisory committee vote against the benefit/risk profile of TLANDO, its oral testosterone replacement therapy (TRT), the company believes there is...

January 23, 2018

Feature

Lipocine advancing pipeline, PDUFA for oral TRT

By Len Zehr With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing...

May 31, 2016

Tag - TLANDO

FDA advisory vote on TLANDO not a knockout for Lipocine

Lipocine advancing pipeline, PDUFA for oral TRT

General

More